ВОЗМОЖНОСТЬ ПРИМЕНЕНИЯ НОВЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ У ПАЦИЕНТОВ ПРИ ПРОВЕДЕНИИ АБЛАЦИИ ПО ПОВОДУ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
https://doi.org/10.15829/1560-4071-2014-12-85-95
Аннотация
В обзоре представлены современные подходы к антикоагулянтной терапии при проведении катетерной радиочастотной аблации фибрилляции предсердий. Обсуждаются возможности различных вариантов перипроцедурального использования варфарина, показаны некоторые результаты исследований, эффективность и безопасность ряда новых пероральных антикоагулянтов при катетерной аблации.
Ключевые слова
Об авторах
Б. А. Татарский
Федеральный медицинский исследовательский центр им. В. А. Алмазова, Санкт-Петербург
Россия
Доктор медицинских наук, профессор, руководитель НИЛ нарушений ритма сердца
Россия
Доктор медицинских наук, профессор, руководитель НИЛ нарушений ритма сердца
Р. Е. Баталов
Научно-исследовательский институт кардиологии, Томск
Россия
Старший научный сотрудник отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции
Россия
Старший научный сотрудник отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции
С. В. Попов
Научно-исследовательский институт кардиологии, Томск
Россия
Доктор медицинских наук, профессор, чл.-корр. РАН, руководитель отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции, заместитель директора по научной и лечебной работе
Россия
Доктор медицинских наук, профессор, чл.-корр. РАН, руководитель отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции, заместитель директора по научной и лечебной работе
Список литературы
1. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–88.
2. Camm J, Up G, De Caterina R, et al. Atrial fibrillation (management of) 2010 and focused update (2012), ESC clinical practice guidelines. Eur Heart J 2012;33:2719-47.
3. Calkins H, Kuck K, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528–606.
4. Kneeland P, Fang M. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009;4:E1–E5.
5. Hart R, Benavente O, McBride R. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492.
6. Smerli G, Lynch S, Fertel S, et al. The difficulties in anticoagulation therapy with warfarin. J Thromb Thrombolysis 2009;27(3):293-9.
7. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. International journal of Cardiology 2012;34(5):176-185.
8. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381-91.
9. Mardigyan V, Verma A, Birnie D, et al. Anticoagulation Management Preand Post-AF ablation: A survey of Canadian centers. Can J Cardiol. 2012;29:219–23.
10. Tapanainen J, Braunschweig R, Schwieler J, et al. Continuous warfarin therapy is sate and feasible in catheter ablation of atrial fibrillation. Scand Cardiovasc J 2013;47(2):109-13.
11. Birnie D, Healey J, Wells G, et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084–93.
12. Di Biase L, Bunkhardt J, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550–56.
13. Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302–11.
14. Periprocedural stroke and bleeding complications in patents undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129{25):2638-44.
15. Healey J, Eikelboom J, Douketis J. Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012:126:343-348.
16. Diagnostics and treatment of atrial fibrillation. In: The Recommendations of the Russian Society of Cardiology, Pan-Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, and the Association of Cardiovascular Surgeons of Russia. Moscow. 2012. 100 pp. Russian (Диагностика и лечение фибрилляции предсердий: рекомендации РКО. ВНОА и АССХ. М., 2012. 100 с.)
17. Heidbuchel H, Verhamme R, Alings M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34(27):2094-106.
18. Lakkireddy D, Reddy Y, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59(13):1168-74.
19. Winkle R, Mead H, Engel G et al. Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Ablation for Atrial Fibrillation. J Am Coll Cardiol 2012;60(12): 1118-19.
20. Kim J, She F, Jongnarangsin K, et al. Dabigatran vs. warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2012;10:483–9.
21. Pandya B, Schwartz L, Shah N, et al. Does Pre-procedural Dabigatran The Need Of Higher Heparin Dosage During Atrial Fibrillation Ablation Procedure? Poster Session VI, Heart Rhythm,2013.
22. Nin T, Sairaku A, Yoshida Y et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:172–9.
23. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460–6.
24. Arshad A, Buch E, Hamam I, et al. Comparative safety of anticoagulation strategies periablation for atrial fibrillation: Data from a large multicenter study. Heart Rhythm 2013, Abstract #AB33-02.
25. Providencia R, Albenque J, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014;100:324–35.
26. Hohnloser S, Camm J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15(10):1407-11.
27. Di Biase L, Burkhardt D, Gilbert G, et al. Dabigratan Has a Higher Risk of Left Atrial Appendage Thrombus Formation in Patients With Af When Compared to Warfarin and Rivaroxaban. http://www.abstractsonline.com /Plan/ViewAbstract. Dallas, 2013.
28. Steinberg B, Hasselblad V, Atwater B, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.J.Interv.Card. Electrophysiol. 2013; 37:213–21.
29. Kaess B, Ammar S, Reents T, et al. Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias under Continuous Anticoagulation with Apixaban versus Phenprocoumon. Published Online: October 11, 2014.
30. Lakkireddy D, Reddy M, Swarup V, et al. Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: A multicentre experience. Heart Rhythm 2013, Abstract #AB33-01.
31. Dillier R, Ammar S, Reents T et al. Safety and Efficacy of Continuous Periprocedural Rivaroxaban for Patients Undergoing Catheter Ablation Procedures: A Retrospective Registry Analysis. Heart Rhythm, 2013, Abstract #PO03-127.
32. Lakkireddy D, Reddy Y, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective study. J Am Coll Cardiol. 2014;63:982–8.
33. Providencia R, Marijon E, Albenque J-P, et al. Rivaroxaban and Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation. Europace. 2014;16(8):1137-44.
34. Siklody C, Deneke T, Hocini M, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011;58(7):681-8.
35. Haines D, Stewart M, Dahlberg S, et al. Microembolism and catheter ablation I: A comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol 2013; 6:16–22.
36. Bohnen M, Stevenson W, Tedrow U, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm. 2011;8:1661–66.
37. Nagy-Balo E, Tint D, Clemens M, et al. Transcranial measurement of cerebral microembolic signals during pulmonary vein isolation: a comparison of two ablation techniques. Circ Arrhythm Electrophysiol. 2013;6:473–80.
38. Ichiki H, Oketani N, Ishida S, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Pacing and Clinical Electrophysiology 2013;36(111):1328-35.
Рецензия
Для цитирования:
Татарский Б.А., Баталов Р.Е., Попов С.В. ВОЗМОЖНОСТЬ ПРИМЕНЕНИЯ НОВЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ У ПАЦИЕНТОВ ПРИ ПРОВЕДЕНИИ АБЛАЦИИ ПО ПОВОДУ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Российский кардиологический журнал. 2014;(12):85-95. https://doi.org/10.15829/1560-4071-2014-12-85-95
For citation:
Tatarsky B.A., Batalov R.E., Popov S.V. POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2014;(12):85-95. (In Russ.) https://doi.org/10.15829/1560-4071-2014-12-85-95
Просмотров:
650
Послать статью по эл. почте 